Navigation Links
CHMP Recommends Approval of BYETTA® for Use With Basal Insulin
Date:2/17/2012

SAN DIEGO and INDIANAPOLIS, Feb. 17, 2012 /PRNewswire/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) and Eli Lilly and Company (NYSE: LLY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion in the European Union (EU) for the expanded use of BYETTA® (exenatide twice-daily) as an add-on therapy to basal insulin, with or without metformin and/or Actos® (pioglitazone), for the treatment of type 2 diabetes in adults who have not achieved adequate glycemic control with these agents. The CHMP's decision is now referred for final action to the European Commission, which has the authority to approve medicines for the EU. The Commission usually decides on CHMP recommendations within two to three months.

"The combination of BYETTA with basal insulin has potential as a complementary treatment approach for several reasons," said Christian Weyer, M.D., senior vice president, research and development, Amylin Pharmaceuticals. "BYETTA is given in a fixed-dose regimen. Its effects contribute to improved glycemic control after meals, complementing the control of fasting blood sugar achieved with basal insulin. And in a clinical study, patients using BYETTA with insulin glargine achieved better glycemic control, without weight gain or an increased risk of hypoglycemia, than patients using insulin glargine without BYETTA."

The double-blind clinical trial evaluating BYETTA as an add-on therapy to insulin glargine was published in Annals of Internal Medicine.[1] In the 30-week study, BYETTA 10 micrograms or placebo was added to existing insulin glargine therapy (with or without metformin, pioglitazone or both), which was titrated to achieve target fasting glucose levels. At study entry, patients wh
'/>"/>

SOURCE Amylin Pharmaceuticals, Inc. and Eli Lilly and Company
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. CHMP Recommends Expanded Use of Angiox(R) (Bivalirudin) in Europe for Patients With Acute Coronary Syndromes
2. Independent Data Safety Monitoring Board Recommends Continuation of Sangarts Pivotal Phase III Trials of Hemospan(R) Following Second Interim Review
3. FDA Advisory Committee Unanimously Recommends U.S. Approval of Sugammadex, the First and Only Selective Relaxant Binding Agent
4. FDA Advisory Committee Unanimously Recommends Approval of Ustekinumab for Treatment of Moderate to Severe Plaque Psoriasis
5. Task Force Recommends Screening for Hearing Loss in All Newborns
6. CHMP Recommends Approval of New Indication for Enbrel(R) as Treatment for Severe Psoriasis in Paediatric Patients
7. Arthritis Advisory Committee Recommends FDA Approval of Febuxostat for the Treatment of Hyperuricemia in Patients With Gout
8. CHMP Recommends Approval in the European Union (EU) for New Options for Patients With Certain Primary Brain Tumors
9. Independent Data Monitoring Committee Recommends Resuming Enrollment of Non-Squamous NSCLC Patients in the Motesanib MONET1 Trial
10. Task Force Recommends Using Aspirin to Prevent Cardiovascular Disease When the Benefits Outweigh the Harms
11. FDA Advisory Committee Recommends Approval of Multaq(R) (dronedarone)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... YORK , August 3, 2015 ... published by Persistence Market Research "Global Market Study ... to Witness Highest Growth by 2022", the ... US$15 Bn by the end of 2015 and is ... from 2015 to 2022, to account for US$23.7 ...
(Date:8/3/2015)... SPRINGS, Florida , August 3, 2015 ... development agreements between biotech companies, military surgical ... solutions & therapies with regards to severe ... positive clinical enhancements for regenerative medicine and ... recent developments, partnerships and advancements in focus ...
(Date:8/3/2015)... , Aug. 3, 2015 VWR (NASDAQ: ... services and solutions, announces the redesign of its global website, ... When visiting the new site, guests will enjoy ... colors and vivid images.  Each country site now includes: ... to Z product menu; and , the ability to ...
Breaking Medicine Technology:Global Physiotherapy Equipment Market Will Reach US$ 23.7 Billion by 2022: Persistence Market Research 2Global Physiotherapy Equipment Market Will Reach US$ 23.7 Billion by 2022: Persistence Market Research 3Global Physiotherapy Equipment Market Will Reach US$ 23.7 Billion by 2022: Persistence Market Research 4Biotech Advancements Coupled with Collaborative Partnerships Focus on Developing Orphan Drug Products & Treatments for Critical-Care Patients With Severe Wound Conditions 2Biotech Advancements Coupled with Collaborative Partnerships Focus on Developing Orphan Drug Products & Treatments for Critical-Care Patients With Severe Wound Conditions 3Biotech Advancements Coupled with Collaborative Partnerships Focus on Developing Orphan Drug Products & Treatments for Critical-Care Patients With Severe Wound Conditions 4Biotech Advancements Coupled with Collaborative Partnerships Focus on Developing Orphan Drug Products & Treatments for Critical-Care Patients With Severe Wound Conditions 5Biotech Advancements Coupled with Collaborative Partnerships Focus on Developing Orphan Drug Products & Treatments for Critical-Care Patients With Severe Wound Conditions 6VWR's New Website Redesign Provides Improved Functionality for Customers 2
... results, SAN DIEGO, April 9, 2008 ... Meeting suggest that an all-natural dietary,supplement made from ... lower,their blood glucose numbers after a meal and ... PhD, KGK Synergize Inc.,s Scientific Director,said, "Our scientifically ...
... Calif., April 9, 2008 ,Sunesis Pharmaceuticals, Inc. (Nasdaq: ... present data on each of its clinical-stage anticancer,compounds ... Association for,Cancer Research (AACR) being held April 12-16 ... of product candidates in oncology focused on novel,pathways ...
Cached Medicine Technology:People With Diabetes May Have All-Natural Citrus Supplement To Help Lower Blood Glucose and Cholesterol Levels 2People With Diabetes May Have All-Natural Citrus Supplement To Help Lower Blood Glucose and Cholesterol Levels 3Sunesis Pharmaceuticals to Present Non-Clinical Data at the Annual Meeting of the American Association for Cancer Research 2Sunesis Pharmaceuticals to Present Non-Clinical Data at the Annual Meeting of the American Association for Cancer Research 3
(Date:8/3/2015)... ... 2015 , ... Bayer has agreed to pay $56.9 million to set up ... alleged to have suffered an arterial blood clot including stroke and heart attack. The ... Ocella, has been ongoing for well-over five years. In 2009, lawsuits filed against Bayer ...
(Date:8/3/2015)... ... August 03, 2015 , ... Novation, the nation’s ... offer pharmacogenetic lab testing and precision medicine solutions that can help pharmacists and ... Annually, more than 8.6 million adverse drug events are reported in the U.S. ...
(Date:8/3/2015)... ... August 03, 2015 , ... Social ... , AUGUST 3, 2015 – Since winning a South by Southwest® (SXSW®) Interactive ... – an organization whose mission is to develop technology for the sake of ...
(Date:8/3/2015)... ... August 03, 2015 , ... ... it’s new program “Designing Secure Healthcare Systems” This three-day, highly interactive and ... from healthcare organizations with access to the tactics, techniques and practices required to ...
(Date:8/3/2015)... (PRWEB) , ... August 03, 2015 , ... ... is predicted to decline by 39 percent, according to market research compiled for ... includes data from the U.S. Department of Labor, Bureau of Labor Statistics. As ...
Breaking Medicine News(10 mins):Health News:Bayer Agrees To Settle Yaz Aterial Blood Clot Lawsuits 2Health News:Novation Awards Genelex First Group Purchasing Agreement for Pharmacogenetic Testing and Precision Medicine Software 2Health News:Novation Awards Genelex First Group Purchasing Agreement for Pharmacogenetic Testing and Precision Medicine Software 3Health News:Not Impossible Earns Top Awards for Technologies Benefiting Humanity 2Health News:Not Impossible Earns Top Awards for Technologies Benefiting Humanity 3Health News:Not Impossible Earns Top Awards for Technologies Benefiting Humanity 4Health News:Sensato and Divurgent are pleased to announce the development of it’s new program “Designing Secure Healthcare Systems” 2Health News:Sensato and Divurgent are pleased to announce the development of it’s new program “Designing Secure Healthcare Systems” 3Health News:Sensato and Divurgent are pleased to announce the development of it’s new program “Designing Secure Healthcare Systems” 4Health News:Dental Association Announces Impending Reduction of Dental Laboratories Could Impact Dentists 2Health News:Dental Association Announces Impending Reduction of Dental Laboratories Could Impact Dentists 3
... A novel research finding from the investigators of Ohio ... of combination of metals like copper with organic chemicals ... range of diseases that are caused by virus.// ... of HIV and Hepatitis C virus RNA in the ...
... of middle-aged women and is characterized by recurring discomfort ... Symptoms vary and can include a combination of mild ... and pelvic area; and an urgent and/or frequent need ... become scarred or irritated, and pinpoint bleeding may appear ...
... HIV infection among its cadres, the Border Security Force ... outpost along West Bengal's international boundary. // ... launched in collaboration with the state AIDS control society ... troopers. ,"We are setting up these condom counters ...
... household activities like cleaning the house and the backyards, ... of prehypertension in people. // ,The study ... daily lifestyle physical activity had the effect of dropping ... hypertensive to prehypertensive and from prehypertensive to normal -- ...
... discriminate between self and non-self. If not for the ... would have lost its power to fight against diseases ... system produces certain substances called antibodies, which identify the ... "bad" so that other divisions of the immune system ...
... strong and science weak, men mistook magic for medicine; now, ... for magic. ~Thomas Szasz, The Second Sin, 1973 ... regarded as a forbidden organ too delicate to tamper with. ... World War II. Military doctors, facing injury and suffering on ...
Cached Medicine News:Health News:Metal In Medicines Can Fight Diseases Effectively 2Health News:Marijuana-Derived Drug Promises Hope In Treating Bladder Infection 2Health News:Free Condom Counters For Border Security Force Cadres 2Health News:Fighting against disease as easy as eating eggs 2Health News:Statins Taken For Reducing Cholesterol Found To Reduce Death Rate Associated With Heart Attack As Well 2
... System includes: Mx3005P instrument and custom ... five (5) filters. The standard filter ... HEX/JOE/VIC (535nm-555nm), ROX/Texas Red (585nm-610nm), Cy5 ... includes notebook computer, Mx3005P analysis software, ...
... temperature cyclers, the gradient block can be set ... to 14 or 22 across the 40- or ... up to 2C between adjacent wells in each ... 12 different annealing temperatures in a single experiment. ...
... The system includes: Mx3005P instrument and ... of five (5) filters. The standard ... (492nm-516nm), HEX/JOE/VIC (535nm-555nm), ROX/Texas Red (585nm-610nm), ... included: desktop computer, Mx3005P analysis software, ...
... includes: Mx3005P instrument and custom filter ... (5) filters. The standard filter set ... (535nm-555nm), ROX/Texas Red (585nm-610nm), Cy5 (635nm-665nm) ... computer, Mx3005P analysis software, Beacon Designer ...
Medicine Products: